Literature DB >> 2526328

Biologic activity of 5'-deoxy-5-fluorouridine by rectal administration.

S L Bramer1, L C Gunnarsson, J L Au.   

Abstract

5'-Deoxy-5-fluorouridine (dFUR) is used orally to treat human malignancies. This study compared the antitumor activity and toxicity of rectally and orally administered dFUR. A 7-day treatment of dFUR (350 or 700 mg/kg/day) was infused rectally over 30 min or administered by oral gavage (500 mg/kg/day) to rats bearing transplanted dimethylhydrazine-induced colon tumors. The oral treatment was previously shown to produce a 82% cure of the tumor-bearing animals. The tumor weight after 7 day treatment was compared to that before treatment. The size of the tumor in the saline-treated control group (N = 6) increased by 55%. The maximum tumor size reductions by drug treatments were 40% for the 350-mg/kg rectal dose (N = 5), greater than 99% for the 700-mg/kg rectal dose (N = 10), and 100% for the 500-mg/kg oral dose (N = 4). The 350-mg/kg rectal dose did not produce any cures, while the 700-mg/kg rectal dose produced 80% cures and the 500-mg/kg oral dose 100% cures. The cured animals remained tumor-free during the observation period of 163 to 243 days. The tumor-bearing rats were euthanized between 46 and 132 days when they appeared moribund or when the tumor began to ulcerate. The 700-mg/kg rectal and 500-mg/kg oral treatments produced greater weight loss than saline suggesting a drug-induced intestinal toxicity. After rectal drug treatment, the animal weight returned to pretreatment level within 3 days, indicating a rapidly reversible intestinal toxicity. The oral group suffered a greater weight loss than the rectal group and took more than 10 days to recover.2+his suggests that the intestinal

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2526328     DOI: 10.1023/a:1015950508618

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Biological activities of 5-fluorouracil and its prodrug 5'-deoxy-5-fluorouridine in rats.

Authors:  J L Au; Y M Rustum; H K Slocum
Journal:  Cancer Drug Deliv       Date:  1987

2.  Phase II study of 5'-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma.

Authors:  P Alberto; M Rozencweig; M Clavel; P Siegenthaler; F Cavalli; S Gundersen; U Bruntsch; J Renard; H Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Pharmacokinetic studies of 5-fluorouracil and 5'-deoxy-5-fluorouridine in rats.

Authors:  J L Au; J S Walker; Y Rustum
Journal:  J Pharmacol Exp Ther       Date:  1983-10       Impact factor: 4.030

4.  Role of administration route in the therapeutic efficacy of doxifluridine.

Authors:  F Trave; L Canobbio; J L Au; Y M Rustum
Journal:  J Natl Cancer Inst       Date:  1987-03       Impact factor: 13.506

5.  Avoidance of "first-pass" elimination of rectally administered lidocaine in relation to the site of absorption in rats.

Authors:  L G de Leede; A G de Boer; C P Roozen; D D Breimer
Journal:  J Pharmacol Exp Ther       Date:  1983-04       Impact factor: 4.030

6.  A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer.

Authors:  I Taylor; D Machin; M Mullee; G Trotter; T Cooke; C West
Journal:  Br J Surg       Date:  1985-05       Impact factor: 6.939

7.  Absorption of 5'-deoxy-5-fluorouridine from colon.

Authors:  J L Au; L C Gunnarsson
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

8.  Phase I clinical study with 5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative.

Authors:  R Abele; P Alberto; R J Seematter; G Germano; R Heintz; W Bollag
Journal:  Cancer Treat Rep       Date:  1982-06
  8 in total
  2 in total

1.  Absorption of 2',3'-dideoxyinosine from lower gastrointestinal tract in rats and kinetic evidence of different absorption rates in colon and rectum.

Authors:  S L Bramer; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

2.  Absorption of 5'-deoxy-5-fluorouridine from colon.

Authors:  J L Au; L C Gunnarsson
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.